Central relaxin-3 receptor (RXFP3) activation decreases anxiety- and depressive-like behaviours in the rat

Behavioural Brain Research

Volumn 244, Issue , 2013, Pages 142-151

  Ryan, Philip J ^a   Büchler, Elena ^a,c   Shabanpoor, Fazel ^a,d   Hossain, Mohammed Akhter ^a,b   Wade, John D ^a,b   Lawrence, Andrew J ^a,b   Gundlach, Andrew L ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^d MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Anxiety; Corticotropin releasing factor; Depression; Relaxin 3; Stress

Indexed keywords

ANTIDEPRESSANT AGENT; RELAXIN 3; RELAXIN 3 RECEPTOR; RXFP3 A2; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; ELEVATED PLUS MAZE; EXPERIMENTAL TEST; EXPOSURE; FORCED SWIMMING TEST; IMMOBILIZATION; LIGHT DARK BOX TEST; MALE; MAZE TEST; MENTAL STRESS; NEUROMODULATION; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSION; INJECTIONS, INTRAVENTRICULAR; MALE; NERVE TISSUE PROTEINS; PEPTIDES; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RELAXIN;

EID: 84874519820     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.01.034     Document Type: Article

References (85)

1. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005, 62:593-602.
2. World Health Organization. The global burden of disease: 2004 update. Geneva: WHO, Press, World Health Organization; 2008.
3. Wang P.S., Insel T.R. NIMH-funded pragmatic trials: moving on. Neuropsychopharmacology 2010, 35:2489-2490.
4. Covington H.E., Vialou V., Nestler E.J. From synapse to nucleus: novel targets for treating depression. Neuropharmacology 2010, 58:683-693.
5. Bale T.L., Vale W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annual Review of Pharmacology and Toxicology 2004, 44:525-557.
6. Binder E.B., Nemeroff C.B. The CRF system, stress, depression and anxiety-insights from human genetic studies. Molecular Psychiatry 2010, 15:574-588.
7. Bathgate R.A.D., Samuel C.S., Burazin T.C.D., Layfield S., Claasz A.A., Reytomas I.G., et al. Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. Novel members of the relaxin peptide family. Journal of Biological Chemistry 2002, 277:1148-1157.
8. Burazin T.C.D., Bathgate R.A.D., Macris M., Layfield S., Gundlach A.L., Tregear G.W. Restricted, but abundant, expression of the novel rat gene-3 (R3) relaxin in the dorsal tegmental region of brain. Journal of Neurochemistry 2002, 82:1553-1557.
9. Tanaka M., Iijima N., Miyamoto Y., Fukusumi S., Itoh Y., Ozawa H., et al. Neurons expressing relaxin 3/INSL 7 in the nucleus incertus respond to stress. European Journal of Neuroscience 2005, 21:1659-1670.
10. Goto M., Swanson L.W., Canteras N.S. Connections of the nucleus incertus. Journal of Comparative Neurology 2001, 438:86-122.
11. Olucha-Bordonau F.E., Teruel V., Barcia-Gonzalez J., Ruiz-Torner A., Valverde-Navarro A.A., Martinez-Soriano F. Cytoarchitecture and efferent projections of the nucleus incertus of the rat. Journal of Comparative Neurology 2003, 464:62-97.
12. Ryan P.J., Ma S., Olucha-Bordonau F.E., Gundlach A.L. Nucleus incertus - an emerging modulatory role in arousal, stress and memory. Neuroscience and Biobehavioral Reviews 2011, 35:1326-1341.
13. Bittencourt J.C., Sawchenko P.E. Do centrally administered neuropeptides access cognate receptors? An analysis in the central corticotropin-releasing factor system. Journal of Neuroscience 2000, 20:1142-1156.
14. 1 activation. Neuropharmacology 2010, 58:145-155.
15. Sutton S.W., Bonaventure P., Kuei C., Roland B., Chen J., Nepomuceno D., et al. Distribution of G-protein-coupled receptor (GPCR)135 binding sites and receptor mRNA in the rat brain suggests a role for relaxin-3 in neuroendocrine and sensory processing. Neuroendocrinology 2004, 80:298-307.
16. Ma S., Bonaventure P., Ferraro T., Shen P.J., Burazin T.C.D., Bathgate R.A.D., et al. Relaxin-3 in GABA projection neurons of nucleus incertus suggests widespread influence on forebrain circuits via G-protein-coupled receptor-135 in the rat. Neuroscience 2007, 144:165-190.
17. Davis M., Walker D.L., Miles L., Grillon C. Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology 2010, 35:105-135.
18. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
19. Lemonde S., Turecki G., Bakish D., Du L., Hrdina P.D., Bown C.D., et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. Journal of Neuroscience 2003, 23:8788-8799.
20. Millan M.J. The role of monoamines in the actions of established and " novel" antidepressant agents: a critical review. European Journal of Pharmacology 2004, 500:371-384.
21. Ressler K.J., Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety 2000, 12(Suppl. 1):2-19.
22. Akimova E., Lanzenberger R., Kasper S. The serotonin-1A receptor in anxiety disorders. Biological Psychiatry 2009, 66:627-635.
23. Richardson-Jones J.W., Craige C.P., Nguyen T.H., Kung H.F., Gardier A.M., Dranovsky A., et al. Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. Journal of Neuroscience 2011, 31:6008-6018.
24. Forster G.L., Pringle R.B., Mouw N.J., Vuong S.M., Watt M.J., Burke A.R., et al. Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activity. European Journal of Neuroscience 2008, 28:299-310.
25. Miyamoto Y., Watanabe Y., Tanaka M. Developmental expression and serotonergic regulation of relaxin 3/INSL7 in the nucleus incertus of rat brain. Regulatory Peptides 2008, 145:54-59.
26. Watanabe Y., Miyamoto Y., Matsuda T., Tanaka M. Relaxin-3/INSL7 regulates the stress-response system in the rat hypothalamus. Journal of Molecular Neuroscience 2011, 43:169-174.
27. McGowan B.M., Stanley S.A., Ghatei M.A., Bloom S.R. Relaxin-3 and its role in neuroendocrine function. Annals of the New York Academy of Sciences 2009, 1160:250-255.
28. Watanabe Y., Tsujimura A., Takao K., Nishi K., Ito Y., Yasuhara Y., et al. Relaxin-3-deficient mice showed slight alteration in anxiety-related behavior. Frontiers in Behavioral Neuroscience 2011, 5:50.
29. Smith C.M., Hosken I.T., Sutton S.W., Lawrence A.J., Gundlach A.L. Relaxin-3 null mutation mice display a circadian hypoactivity phenotype. Genes, Brain and Behavior 2012, 11:94-104.
30. Liu C., Chen J., Kuei C., Sutton S., Nepomuceno D., Bonaventure P., et al. Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7. Molecular Pharmacology 2005, 67:231-240.
31. Ma S., Kastman H., Olucha-Bordonau F.E., Capogna M., Hossain M.A., Wade J.D., et al. Relaxin-3 receptor activation in central amygdala enhances fear extinction in the rat: implications for relaxin-3 control of emotion. Society for Neuroscience - Abstract 2010, 809.24.
32. Shabanpoor F., Akhter Hossain M., Ryan P.J., Belgi A., Layfield S., Kocan M., et al. Minimization of human relaxin-3 leading to high-affinity analogues with increased selectivity for relaxin-family peptide 3 receptor (RXFP3) over RXFP1. Journal of Medicinal Chemistry 2012, 55:1671-1681.
33. Belzung C., Le Pape G. Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety. Physiology & Behavior 1994, 56:623-628.
34. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
35. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. European Journal of Pharmacology 1978, 47:379-391.
36. Borsini F., Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity?. Psychopharmacology 1988, 94:147-160.
37. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neuroscience and Biobehavioral Reviews 2005, 29:547-569.
38. McGowan B.M., Stanley S.A., Smith K.L., White N.E., Connolly M.M., Thompson E.L., et al. Central relaxin-3 administration causes hyperphagia in male Wistar rats. Endocrinology 2005, 146:3295-3300.
39. Bathgate R.A.D., Lin F., Hanson N.F., Otvos L.J., Guidolin A., Giannakis C., et al. Relaxin-3: improved synthesis strategy and demonstration of its high-affinity interaction with the relaxin receptor LGR7 both in vitro and in vivo. Biochemistry 2006, 45:1043-1053.
40. Kuei C., Sutton S., Bonaventure P., Pudiak C., Shelton J., Zhu J., et al. R3(B(23-27)R/I5 chimeric peptide, a selective antagonist for GPCR135 and GPCR142 over relaxin receptor LGR7: in vitro and in vivo characterization. Journal of Biological Chemistry 2007, 282:25425-25435.
41. Otsubo H., Onaka T., Suzuki H., Katoh A., Ohbuchi T., Todoroki M., et al. Centrally administered relaxin-3 induces Fos expression in the osmosensitive areas in rat brain and facilitates water intake. Peptides 2010, 31:1124-1130.
42. Haugaard-Jonsson L.M., Hossain M.A., Daly N.L., Bathgate R.A.D., Wade J.D., Craik D.J., et al. Structure of the R3/I5 chimeric relaxin peptide, a selective GPCR135 and GPCR142 agonist. Journal of Biological Chemistry 2008, 283:23811-23818.
43. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Academic Press, London. sixth ed.
44. Kliethermes C.L., Cronise K., Crabbe J.C. Anxiety-like behavior in mice in two apparatuses during withdrawal from chronic ethanol vapor inhalation. Alcoholism, Clinical and Experimental Research 2004, 28:1012-1019.
45. Featherby T., van den Buuse M., Lubman D.I., Lawrence A.J. Persistent downregulation of hippocampal CREB mRNA parallels a Y-maze deficit in adolescent rats following semi-chronic amphetamine administration. British Journal of Pharmacology 2008, 154:417-428.
46. Field A. Discovering statistics using SPSS 2009, SAGE Publications Ltd., London, U.K. third ed.
47. Fernandes C., File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacology Biochemistry and Behavior 1996, 54:31-40.
48. File S.E. Factors controlling measures of anxiety and responses to novelty in the mouse. Behavioural Brain Research 2001, 125:151-157.
49. Bourin M., Hascoet M. The mouse light/dark box test. European Journal of Pharmacology 2003, 463:55-65.
50. Crawley J., Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacology Biochemistry and Behavior 1980, 13:167-170.
51. Chaouloff F., Durand M., Mormede P. Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light/dark and dark/light tests. Behavioural Brain Research 1997, 85:27-35.
52. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods 1985, 14:149-167.
53. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
54. Walf A.A., Frye C.A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nature Protocols 2007, 2:322-328.
55. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. European Journal of Pharmacology 2003, 463:3-33.
56. Dulawa S.C., Grandy D.K., Low M.J., Paulus M.P., Geyer M.A. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. Journal of Neuroscience 1999, 19:9550-9556.
57. Goto M. Hodological and functional study of the nucleus incertus and pars alfa of the pontine periventricular gray 1998, University of Sao Paulo, Brazil, Sao Paulo.
58. McIlwain K.L., Merriweather M.Y., Yuva-Paylor L.A., Paylor R. The use of behavioral test batteries: effects of training history. Physiology & Behavior 2001, 73:705-717.
59. Borsini F., Lecci A., Sessarego A., Frassine R., Meli A. Discovery of antidepressant activity by forced swimming test may depend on pre-exposure of rats to a stressful situation. Psychopharmacology 1989, 97:183-188.
60. Mitra R., Jadhav S., McEwen B.S., Vyas A., Chattarji S. Stress duration modulates the spatiotemporal patterns of spine formation in the basolateral amygdala. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:9371-9376.
61. Roozendaal B., McEwen B.S., Chattarji S. Stress, memory and the amygdala. Nature Reviews Neuroscience 2009, 10:423-433.
62. Russo S.J., Murrough J.W., Han M.H., Charney D.S., Nestler E.J. Neurobiology of resilience. Nature Neuroscience 2012, 15:1475-1484.
63. Sutton S.W., Shelton J., Smith C.M., Williams J., Yun S., Motley T., et al. Metabolic and neuroendocrine responses to RXFP3 modulation in the central nervous system. Annals of the New York Academy of Sciences 2009, 1160:242-249.
64. Hida T., Takahashi E., Shikata K., Hirohashi T., Sawai T., Seiki T., et al. Chronic intracerebroventricular administration of relaxin-3 increases body weight in rats. Journal of Receptor and Signal Transduction Research 2006, 26:147-158.
65. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. Journal of Endocrinology 1999, 160:1-12.
66. Heilig M., McLeod S., Koob G.K., Britton K.T. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regulatory Peptides 1992, 41:61-69.
67. Suda T., Tozawa F., Iwai I., Sato Y., Sumitomo T., Nakano Y., et al. Neuropeptide Y increases the corticotropin-releasing factor messenger ribonucleic acid level in the rat hypothalamus. Brain Research. Molecular Brain Research 1993, 18:311-315.
68. Smith K.L., Patterson M., Dhillo W.S., Patel S.R., Semjonous N.M., Gardiner J.V., et al. Neuropeptide S stimulates the hypothalamo-pituitary-adrenal axis and inhibits food intake. Endocrinology 2006, 147:3510-3518.
69. Okamura N., Reinscheid R.K. Neuropeptide S: a novel modulator of stress and arousal. Stress 2007, 10:221-226.
70. Takahashi L.K., Kalin N.H., Vanden Burgt J.A., Sherman J.E. Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behavioral Neuroscience 1989, 103:648-654.
71. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., Britton K.T. CRF antagonist reverses the " anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology 1991, 103:227-232.
72. Swerdlow N.R., Geyer M.A., Vale W.W., Koob G.F. Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology 1986, 88:147-152.
73. Thorsell A. Brain neuropeptide Y and corticotropin-releasing hormone in mediating stress and anxiety. Experimental Biology and Medicine (Maywood, N.J.) 2010, 235:1163-1167.
74. Liang K.C., Melia K.R., Campeau S., Falls W.A., Miserendino M.J., Davis M. Lesions of the central nucleus of the amygdala, but not the paraventricular nucleus of the hypothalamus, block the excitatory effects of corticotropin-releasing factor on the acoustic startle reflex. Journal of Neuroscience 1992, 12:2313-2320.
75. Pich E.M., Heinrichs S.C., Rivier C., Miczek K.A., Fisher D.A., Koob G.F. Blockade of pituitary-adrenal axis activation induced by peripheral immunoneutralization of corticotropin-releasing factor does not affect the behavioral response to social defeat stress in rats. Psychoneuroendocrinology 1993, 18:495-507.
76. Britton K.T., Lee G., Vale W., Rivier J., Koob G.F. Corticotropin releasing factor (CRF) receptor antagonist blocks activating and 'anxiogenic' actions of CRF in the rat. Brain Research 1986, 369:303-306.
77. Davis M., Shi C. The extended amygdala: are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety. Annals of the New York Academy of Sciences 1999, 877:281-291.
78. Walker D.L., Toufexis D.J., Davis M. Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. European Journal of Pharmacology 2003, 463:199-216.
79. Shader R.I., Greenblatt D.J. Use of benzodiazepines in anxiety disorders. New England Journal of Medicine 1993, 328:1398-1405.
80. Horvath L., van Marion I., Tai K., Nielsen T.T., Lundberg C. Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease. Journal of Medical Genetics 2011, 13:188-197.
81. Tong Q., Ye C.P., Jones J.E., Elmquist J.K., Lowell B.B. Synaptic release of GABA by AgRP neurons is required for normal regulation of energy balance. Nature Neuroscience 2008, 11:998-1000.
82. Hokfelt T., Broberger C., Xu Z.Q., Sergeyev V., Ubink R., Diez M. Neuropeptides - an overview. Neuropharmacology 2000, 39:1337-1356.
83. van den Pol A.N. Neuropeptide transmission in brain circuits. Neuron 2012, 76:98-115.
84. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nature Reviews Drug Discovery 2005, 4:775-790.
85. Berton O., McClung C.A., Dileone R.J., Krishnan V., Renthal W., Russo S.J., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006, 311:864-868.